| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 05/25/2004 | US6740770 Crystal of bicalutamide and production method thereof |
| 05/25/2004 | US6740325 Peptide-based vaccine for influenza |
| 05/25/2004 | CA2218078C Cosmetic composition including an acrylic anionic polymer and an oxyalkylene silicone |
| 05/21/2004 | WO2004042359A2 Preformulation analysis and optimization |
| 05/21/2004 | WO2004041846A2 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES |
| 05/21/2004 | WO2004041217A2 Synthetic lactone formulations and method of use |
| 05/21/2004 | WO2004041213A2 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| 05/21/2004 | WO2004041212A2 Apkc isoforms in nervous system disorders and cancer |
| 05/21/2004 | WO2004041211A2 INHIBITORS OF β-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER’S DISEASE OR MILD COGNITIVE IMPAIRMENT |
| 05/21/2004 | WO2004041210A2 Antibacterial agents |
| 05/21/2004 | WO2004041204A2 Methods and compositions for treating neurodegenerative diseases |
| 05/21/2004 | WO2004041202A2 Analysis of pharmaceutical solubility and stability |
| 05/21/2004 | WO2004041199A2 N-acetyl-d-glucosamine (nag) supplemented food products and beverages |
| 05/21/2004 | WO2004041198A2 Heat pasteurized liquids containing glucosamine |
| 05/21/2004 | WO2004041196A2 Methods and compositions for the diagnosis of neuroendocrine lung cancer |
| 05/21/2004 | WO2004041195A2 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 05/21/2004 | WO2004041194A2 Inhibition of hiv-1 replication |
| 05/21/2004 | WO2004041193A2 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5 |
| 05/21/2004 | WO2004041192A2 Panels of molecular targets differentially expressed during cd8+ t-cell priming |
| 05/21/2004 | WO2004041188A2 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | WO2004041187A2 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | WO2004041186A2 Anti-angiogenesis effects of morinda citrifolia |
| 05/21/2004 | WO2004041182A2 M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever |
| 05/21/2004 | WO2004041180A2 Compositions for lowering blood pressure |
| 05/21/2004 | WO2004041179A2 Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation |
| 05/21/2004 | WO2004041177A2 Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| 05/21/2004 | WO2004041172A2 Interferon antagonists useful for the treatment of interferon related diseases |
| 05/21/2004 | WO2004041168A2 Compositions and methods for prevention of photoaging |
| 05/21/2004 | WO2004041164A2 Kinase inhibitors |
| 05/21/2004 | WO2004041160A2 Methods and animal model for analyzing age-related macular degeneration |
| 05/21/2004 | WO2004041159A2 Composition and method for enhancing immune response of swine |
| 05/21/2004 | WO2004040997A2 Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine |
| 05/21/2004 | WO2004028452A3 Method for preparing crambescidin core acid intermediates and their use for preparing crambescidin alkaloid analogs as therapeutic agents |
| 05/21/2004 | WO2004024087A9 Methods of diagnosing and treating hyperproliferative disorders |
| 05/21/2004 | WO2004014321A3 Compositions having a pearl blend appearance additive, personal care products made therefrom |
| 05/21/2004 | WO2004004629A3 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 05/21/2004 | WO2003072040A3 Administration of agents for the treatment of inflammation |
| 05/21/2004 | CA2718277A1 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | CA2543376A1 Interferon antagonists useful for the treatment of interferon related diseases |
| 05/21/2004 | CA2504870A1 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| 05/21/2004 | CA2504593A1 Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| 05/21/2004 | CA2504379A1 Compositions and methods for prevention of photoaging |
| 05/21/2004 | CA2504350A1 Apkc isoforms in nervous system disorders and cancer |
| 05/21/2004 | CA2504125A1 Inducible ligand for .alpha.1.beta.1 integrin and uses |
| 05/21/2004 | CA2504021A1 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | CA2503715A1 Kinase inhibitors |
| 05/21/2004 | CA2503150A1 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 05/21/2004 | CA2502864A1 Heat pasteurized liquids containing glucosamine |
| 05/21/2004 | CA2501523A1 Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| 05/20/2004 | US20040097720 Use of glycodendrimer reagents for inhibiting adhesion by microorganisms |
| 05/20/2004 | US20040097500 Compounds and compositions for delivering active agents |
| 05/20/2004 | US20040097462 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/20/2004 | US20040097430 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 05/20/2004 | US20040096889 Compositions, organisms and methodologies employing a novel human kinase |
| 05/20/2004 | US20040096829 Absolute quantitation of nucleic acids by RT-PCR |
| 05/20/2004 | US20040096526 Using plant extracts mixtures; extraction, filtration, spray drying; beverages |
| 05/20/2004 | US20040096500 Reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is |
| 05/20/2004 | US20040096444 Identification of the endothelial receptor for the angiostatin kringle-5 |
| 05/20/2004 | US20040096422 Methods for reducing pain and organ dysfunction using bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, |
| 05/20/2004 | US20040096399 Inhalers containing a solution of an active ingredient in a hydrofluorocarbon propellant and a cosolvent; the internal surfaces consist of stainless steel, anodised aluminium or are lined with an inert organic coating. |
| 05/19/2004 | EP1419776A2 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 05/19/2004 | EP1419152A1 Hiv inhibiting pyrimidines derivatives |
| 05/19/2004 | EP1419150A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 05/19/2004 | EP1418929A2 Simmondsin processing methods and products |
| 05/19/2004 | EP1418924A2 Single dose azithromycin for treating respiratory infections |
| 05/19/2004 | EP1418889A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 05/19/2004 | EP1418814A2 Production of transduced hematopoietic progenitor cells |
| 05/19/2004 | EP0984965B1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors |
| 05/19/2004 | EP0781136B1 Compounds and methods for the treatment of cancer |
| 05/19/2004 | CN1498222A Steroidal derivatives |
| 05/19/2004 | CN1498212A New spirotricyclic derivatives and their use as phosphodiesterase-7-inhibitors |
| 05/19/2004 | CN1498096A Condom with erectogenic composition |
| 05/19/2004 | CN1150217C Cross-linked polymer and its application |
| 05/19/2004 | CN1150192C Piperidines as CCR5 modulators |
| 05/19/2004 | CN1150181C Substituted benzopyran analogs for treatment of inflammation |
| 05/19/2004 | CN1149983C Compositions and methos for treatment of anorectal disorders |
| 05/18/2004 | US6737437 EP4 receptor selective agonists in the treatment of osteoporosis |
| 05/13/2004 | WO2004039430A2 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x |
| 05/13/2004 | WO2004039330A2 Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls |
| 05/13/2004 | WO2004039329A2 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 05/13/2004 | WO2004039328A2 Fludrocortisone treatment for hearing loss |
| 05/13/2004 | WO2004039327A2 Use of equol for treating androgen mediated diseases |
| 05/13/2004 | WO2004039320A2 STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF |
| 05/13/2004 | WO2004039319A2 Novel human polypeptides encoded by polynucleotides |
| 05/13/2004 | WO2004039314A2 Process for synthesizing l-y-methylene glutamic acid and analogs |
| 05/13/2004 | WO2004039313A2 Preventing desensitization of receptors |
| 05/13/2004 | WO2004039308A2 Quinazolinone compositions for regulation of gene expression related to pathological processes |
| 05/13/2004 | WO2004030623A3 Nitroxide radioprotector formulations and methods of use |
| 05/13/2004 | WO2004024078A3 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 05/13/2004 | WO2004019960A3 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
| 05/13/2004 | WO2004014302A3 Mechanisms of myoblast transfer in treating heart failure |
| 05/13/2004 | WO2003077830A3 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives |
| 05/13/2004 | US20040092502 Central nervous system disorders; dietetics; psychological disorders; sleep disorders; sexual disorders |
| 05/13/2004 | US20040092479 Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage |
| 05/13/2004 | US20040091947 Screening strategy for anticancer drugs |
| 05/13/2004 | US20040091525 Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitor component |
| 05/13/2004 | US20040091491 An immune response modifier portion such as a Toll-like receptor or an imidazoquinoline compound paired with an antigenic portion; use of toll-like receptor improves immune response over conventional immune response modifiers |
| 05/13/2004 | US20040091426 Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes |
| 05/13/2004 | CA2505852A1 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 05/13/2004 | CA2504682A1 Use of equol for treating androgen mediated diseases |